Biochemical selection on conserved glycans yield a cross-species AAV capsid for efficient panretinal intravitreal delivery
Year: 2026
Type: preprint
Abstract: Inherited retinal diseases are leading candidates for gene therapy, but photoreceptor-directed adeno-associated virus (AAV) vectors still require subretinal injection, which treats only part of the retina and carries surgical risk. Intravitreal delivery is simple and panretinal, yet inner-retinal barriers block most capsids, and capsids selected in one species rarely translate. Mapping retinal glycans across seven mammals, we found heparan sulfate (HS) marking the inner limiting membrane and terminal N-acetylglucosamine (GlcNAc) enriched on photoreceptor segments. These invariants defined a two-part design principle, attenuated HS binding with strong terminal GlcNAc engagement, implemented as a sequential in vitro selection, Conserved Receptor-Selection Technology (CReST). Its lead GlcNAc-selected capsid, AAV2.IvtB, increased retinal transgene expression 6.5-fold over AAV2.7m8 in mice and photoreceptor transduction 2.5-fold in pigs, acting through terminal GlcNAc engagement. It partially preserved photoreceptors in rd10 mice and suppressed laser-induced choroidal neovascularization. CReST is a receptor-guided, animal-free route to capsids with a defined, conserved mechanism.
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7236855758
